• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新的、强效的尾加压素II受体肽激动剂,其在二硫键处含有一个Pen残基。

A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge.

作者信息

Grieco Paolo, Carotenuto Alfonso, Campiglia Pietro, Zampelli Enrico, Patacchini Riccardo, Maggi Carlo A, Novellino Ettore, Rovero Paolo

机构信息

Department of Pharmaceutical and Toxicological Chemistry, University of Naples Federico II, I-80131 Naples, Italy.

出版信息

J Med Chem. 2002 Sep 26;45(20):4391-4. doi: 10.1021/jm025549i.

DOI:10.1021/jm025549i
PMID:12238917
Abstract

Replacing Cys(5) by Pen (penicillamine, beta,beta-dimethylcysteine) in the cyclic C-terminal U-II octapeptide, U-II(4-11), we have obtained a potent urotensin II (U-II) receptor agonist. Conformational analysis of solution NMR data indicated that the putative biologically active conformation of U-II is stabilized by introduction of a Pen residue. To the best of our knowledge, this is the most potent U-II receptor agonist reported to date.

摘要

在环状C末端U-II八肽U-II(4 - 11)中,用青霉胺(penicillamine,β,β - 二甲基半胱氨酸)取代半胱氨酸(Cys)(5),我们获得了一种强效的尾加压素II(U-II)受体激动剂。溶液核磁共振数据的构象分析表明,引入一个青霉胺残基可稳定U-II假定的生物活性构象。据我们所知,这是迄今为止报道的最强效的U-II受体激动剂。

相似文献

1
A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge.一种新的、强效的尾加压素II受体肽激动剂,其在二硫键处含有一个Pen残基。
J Med Chem. 2002 Sep 26;45(20):4391-4. doi: 10.1021/jm025549i.
2
Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP).二硫键环化的血管紧张素 IV 三肽类似物作为胰岛素调节氨基肽酶(IRAP)的有效和选择性抑制剂。
J Med Chem. 2010 Nov 25;53(22):8059-71. doi: 10.1021/jm100793t. Epub 2010 Nov 3.
3
New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.对尿紧张素II受体处肽配体结合模式的新见解:P5U和尿降压肽的构效关系研究
J Med Chem. 2009 Jul 9;52(13):3927-40. doi: 10.1021/jm900148c.
4
Urotensin-II receptor ligands. From agonist to antagonist activity.尾加压素II受体配体。从激动剂到拮抗剂活性
J Med Chem. 2005 Nov 17;48(23):7290-7. doi: 10.1021/jm058043j.
5
Novel sst5-selective somatostatin dicarba-analogues: synthesis and conformation-affinity relationships.新型sst5选择性生长抑素二碳类似物:合成与构象-亲和力关系
J Med Chem. 2008 Feb 14;51(3):512-20. doi: 10.1021/jm070886i. Epub 2008 Jan 23.
6
Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.新型促生长抑素(sst)(4)选择性生长抑素(SRIF)激动剂。1. 使用β肽扫描进行先导化合物鉴定。
J Med Chem. 2003 Dec 18;46(26):5579-86. doi: 10.1021/jm030243c.
7
Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds.通过环四肽支架的结构调整鉴定新型低分子量CXCR4拮抗剂。
J Med Chem. 2005 May 5;48(9):3280-9. doi: 10.1021/jm050009h.
8
Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.κ-阿片受体对环四肽配体识别中3号和4号残基的作用。
J Pept Res. 2005 Mar;65(3):333-42. doi: 10.1111/j.1399-3011.2005.00220.x.
9
Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.新型促生长抑素(sst)(4)选择性生长抑素(SRIF)激动剂。2. 8位具有β-甲基-3-(2-萘基)丙氨酸取代的类似物。
J Med Chem. 2003 Dec 18;46(26):5587-96. doi: 10.1021/jm0302445.
10
Solution stability of linear vs. cyclic RGD peptides.线性与环状RGD肽的溶液稳定性
J Pept Res. 1999 May;53(5):530-41. doi: 10.1034/j.1399-3011.1999.00052.x.

引用本文的文献

1
Optimization of RGD-Containing Cyclic Peptides against αvβ3 Integrin.含RGD环肽对αvβ3整合素的优化
Mol Cancer Ther. 2016 Feb;15(2):232-40. doi: 10.1158/1535-7163.MCT-15-0544. Epub 2015 Dec 30.
2
A new therapeutic approach to erectile dysfunction: urotensin-II receptor high affinity agonist ligands.勃起功能障碍的一种新治疗方法:尾加压素 II 受体高亲和力激动剂配体
Asian J Androl. 2015 Jan-Feb;17(1):81-5. doi: 10.4103/1008-682X.133322.
3
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.《2013/14药理学简明指南:G蛋白偶联受体》
Br J Pharmacol. 2013 Dec;170(8):1459-581. doi: 10.1111/bph.12445.
4
Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures.尾加压素 II 配体:从肽类结构到非肽类结构的概述
J Amino Acids. 2013;2013:979016. doi: 10.1155/2013/979016. Epub 2013 Feb 25.
5
Endogenous urotensin II selectively modulates erectile function through eNOS.内源性尾加压素 II 通过 eNOS 选择性调节勃起功能。
PLoS One. 2012;7(2):e31019. doi: 10.1371/journal.pone.0031019. Epub 2012 Feb 2.
6
A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.大鼠脑 uro 素 II 受体表达图谱及中枢 uro 素 II 作用综述
Naunyn Schmiedebergs Arch Pharmacol. 2010 Jul;382(1):1-31. doi: 10.1007/s00210-010-0503-z. Epub 2010 Apr 27.
7
Role of urotensin II and its receptor in health and disease.尾加压素II及其受体在健康与疾病中的作用。
J Anesth. 2007;21(3):378-89. doi: 10.1007/s00540-007-0524-z. Epub 2007 Aug 1.
8
Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.横纹肌肉瘤细胞系中天然功能性人尾加压素II受体的鉴定及药理学特性研究
Br J Pharmacol. 2004 Jul;142(6):921-32. doi: 10.1038/sj.bjp.0705743. Epub 2004 Jun 21.
9
Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.尿紧张素拮抗剂:大鼠主动脉中一种超高效的尾加压素II拮抗剂肽。
Br J Pharmacol. 2003 Dec;140(7):1155-8. doi: 10.1038/sj.bjp.0705555.